The company, which is backed by Mitsubishi Tanabe Pharma and tobacco giant Philip Morris, said it planned to move into mid-to-late-stage trials with a lower dose version of its vaccine, along with the GSK adjuvant. “What we’re most encouraged with is that we are able to go with the lowest dose for our phase 2/3 trials,” Medicago’s Chief Executive Officer Bruce Clark told Reuters. Trials from rival coronavirus vaccine developers have generally shown that lower doses produce less side effects. …read more
Source:: Yahoo Finance
